Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0070aep462 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain

luiza luca Bogdana , Miguel Sierra Poyatos Roberto , Cardenas Jersy , Sanchez Gomez Nancy , Jesus Silva Rodriguez Maria , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Sanchez Lopez Raquel , Cruces Vega Eva , Estrella Alicia , Barrio Pilar , Sanchez Lechuga Begoña , Gonzalo Montesinos Irene , Jose De la Cruz Fernandez Maria , Perez Alvarez Enrique , Vazquez Martinez Clotilde

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...
0 shares

ea0070ep197 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

Cardenas Jersy , Sanchez Gomez Nancy , Miguel Sierra Poyatos Roberto , Luiza Luca Bogdana , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Silva Rodriguez Maria Jesus , Ortega Juaristi Maite , Meneses González Diego , De Los Angeles Gonzalo Redondo Maria , Galdon Sanz–Pastor Alba , Ruiz Sanchez Jorge , De La Paz Gómez Montes María , Cruces Vega Cristina , Vazquez Martinez Clotilde

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...
0 shares

ea0073aep809 | Late Breaking | ECE2021

Comparison of the clinical efficacy of Semaglutide between DPP4-inhibitor-naive and DPP4-inhibitor-experienced patients in a real world setting in Spain

Roberto Miguel Sierra Poyatos , Jersy Jair Cardenas Salas , Luiza Luca Bogdana , Nancy María Sanchez Gomez , Naiara Modroño Mostoles , Begoña Sánchez Lechuga , Cruces Vega Eva , Maria Jesus Silva Rodriguez , María De La Paz Gómez Montes , Diego Meneses González , Montoya Alvarez Teresa , María de los Angeles Velez Romero , Estrella Santos Alicia , Ortega Juaristi Maite , Maria De Los Angeles Gonzalo Redondo , Vazquez Martinez Clotilde

IntroductionGlucose and weight control effectiveness in patients with Type 2 diabetes (T2D) in treatment with DPP4 inhibitors (DPP4i) that switch to semaglutide is scarce. We aim to assess it in a real-world setting of DPP4i-experienced patients and compare it to DPP4i-naive patients.MethodsPatients with T2D that were prescribed Once-Weekly semaglutide in 4 hospitals in Madrid-Spain were identified. Patients ...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more